Thrivent Financial for Lutherans’s Xenon Pharmaceuticals XENE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$551K	Hold	9,122	–	–	﹤0.01%	2275
2026 Q1	$531K	Buy	9,122 +3,539	+63%	+$163K	﹤0.01%	2196
2025 Q4	$250K	Sell	5,583 -10,518	-65%	-$442K	﹤0.01%	2472
2025 Q3	$647K	Buy	+16,101	New	+$567K	﹤0.01%	1981
2025 Q1	–	Sell	-30,699	Closed	-$1.2M	–	2567
2024 Q4	$1.2M	Sell	30,699 -12,394	-29%	-$512K	﹤0.01%	1793
2024 Q3	$1.7M	Hold	43,093	–	–	﹤0.01%	1559
2024 Q2	$1.68M	Buy	+43,093	New	+$1.72M	﹤0.01%	1500

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Thrivent Financial for Lutherans's XENE Position: Q2 2026 in Review

Thrivent Financial for Lutherans held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 9,122 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

Thrivent Financial for Lutherans first reported a position in XENE in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.7M in Q3 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Thrivent Financial for Lutherans held 9,122 shares of Xenon Pharmaceuticals worth $551K as of Q2 2026.
Thrivent Financial for Lutherans left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2275 holding.
Thrivent Financial for Lutherans first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
Thrivent Financial for Lutherans's Xenon Pharmaceuticals position peaked at $1.7M in Q3 2024.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.